Therapeutic Areas
The PHARMO Institute has performed more than a thousand of studies since the establishment of the PHARMO Institute in 1999. The intention of the studies is to publish the research findings in international and national medical journals. Below we have grouped publications on specialized recurrent topics.
More specific studies, as well as abstracts and referral to the original publication can be obtained by using the 'search' option in the menu bar.
- Statins
- 1. Geers HC, Bouvy ML, Heerdink ER. Estimates of statin discontinuation rates are influenced by exposure and outcome definitions. Ann Pharmacother. 2011;45(5):576-81.
- 2. van den Haak P, Heintjes E, Plat AW, Jan Meerding W, Webb K, Sturkenboom MC, et al. Determination of non-treatment with statins of high risk patients in The Netherlands. Curr Med Res Opin. 2010;26(2):271-8.
- 3. Peters BJ, Rodin AS, Klungel OH, Stricker BH, de Boer A, Maitland-van der Zee AH. Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenet Genomics. 2010;20(12):766-74.
- 4. McAfee AT, Rodriguez LA, Goettsch WG, Gonzalez-Perez A, Johansson S, Ming EE, et al. Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries. Minerva Cardioangiol. 2010;58(6):611-22.
- 5. Garcia Rodriguez LA, Herings R, Johansson S. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. Pharmacoepidemiol Drug Saf. 2010;19(12):1218-24.
- 6. Risselada R, Straatman H, van Kooten F, Dippel DW, van der Lugt A, Niessen WJ, et al. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke. 2009;40(8):2887-92.
- 7. Heintjes EM, Penning-van Beest FJ, Johansson S, Stalenhoef AF, Herings RM. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Curr Med Res Opin. 2009;25(11):2621-9.
- 8. Peters BJ, Maitland-van der Zee AH, Stricker BH, van Wieren-de Wijer DB, de Boer A, Kroon AA, et al. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenet Genomics. 2008;18(7):631-6.
- 9. Heintjes EM, Hirsch MW, Van der Linden MW, O'Donnell JC, Stalenhoef AF, Herings RMC. LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results. Curr Med Res Opin. 2008;24(8):2241-50
- 10. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Effect of drug combinations on admission for recurrent myocardial infarction. Heart. 2007;93(10):1226-30.
- 11. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007;28(2):154-9.
- 12. Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, et al. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer. 2007;43(17):2580-9.
- 13. Johansson S, E.E. M, M.A. W, L.A. R, Herings RM, Goettsch W, et al. Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiol Drug Saf. 2006;15(7):454-61.
- 14. Goettsch WG, Heintjes EM, Kastelein JJ, Rabelink TJ, Johansson S, Herings RM. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf. 2006;15(7):435-43.
- 15. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis. Clin Ther. 2005;27(11):1806-14.
- 16. Mantel-Teeuwisse AK, Klungel OH, Schalekamp T, Verschuren WM, Porsius AJ, de Boer A. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol. 2005;60(1):83-9.
- 17. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388-94.
- 18. Goettsch WG, Yin DD, Alemao E, Klungel OH, Stalenhoef AF, Herings RM. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin. 2004;20(7):1025-33.
- 19. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius AJ, de Boer A. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol. 2002;53(4):379-85.
- 20. Mantel-Teeuwisse AK, Klungel OH, Herings RM, van Puijenbroek EP, Porsius AJ, de Boer A. Myopathy due to statin/fibrate use in the Netherlands. Ann Pharmacother. 2002;36(12):1957-60.
- 21. Leufkens HG, Herings RM, Urquhart J. Efficacy of low-density-lipoprotein lowering with statins. Lancet. 1994;344(8923):683-4.
- Oncology
- 1. van Herk-Sukel MP, Shantakumar S, Kamphuisen PW, Penning-van Beest FJ, Herings RM. Myocardial infarction, ischaemic stroke and pulmonary embolism before and after breast cancer hospitalisation. A population-based study. Thromb Haemost. 2011;106(1).
- 2. Landis SH, El-Hariry IA, van Herk-Sukel MP, van den Haak P, Janssen-Heijnen ML, Penning-van Beest FJ, et al. Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck. Head Neck. 2011:in press.
- 3. Herk-Sukel MP, Lemmens VE, Poll-Franse LV, Herings RM, Coebergh JW. Record linkage for pharmacoepidemiological studies in cancer patients. Pharmacoepidemiol Drug Saf. 2011. Epub 2011/08/04.
- 4. van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010;122(3):843-51.
- 5. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, Vreugdenhil G, Pruijt JF, Coebergh JW, et al. New opportunities for drug outcomes research in cancer patients: The linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer. 2010;46:395-404.
- 6. Milder IE, Klungel OH, Mantel-Teeuwisse AK, Verschuren WM, Bemelmans WJ. Relation between body mass index, physical inactivity and use of prescription drugs: the Doetinchem Cohort Study. Int J Obes (Lond). 2010;34(6):1060-9.
- 7. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, et al. Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer. J Clin Oncol. 2010(28):2423-9.
- 8. Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary. 2010;13(3):195-8.
- 9. Koomen ER, Herings RM, Guchelaar HJ, Nijsten T. Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cancer Epidemiol. 2009;33(5):391-5.
- 10. Sukel MP, van de Poll-Franse LV, Nieuwenhuijzen GA, Vreugdenhil G, Herings RM, Coebergh JW, et al. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer. 2008:1846-854.
- 11. Sukel MP, Breekveldt-Postma NS, Erkens JA, van der Linden PD, Beiderbeck AB, Coebergh JW, et al. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice. Pharmacoepidemiol Drug Saf. 2008;17(2):125-34.
- 12. Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, et al. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer. 2007;43(17):2580-9.
- 13. Engels FK, de Jong FA, Mathijssen RH, Erkens JA, Herings RM, Verweij J. Medicinal cannabis in oncology. Eur J Cancer. 2007;43(18):2638-44.
- 14. Houben MP, Coebergh JW, Herings RM, Casparie MK, Tijssen CC, van Duijn CM, et al. The association between antihypertensive drugs and glioma. Br J Cancer. 2006;94(5):752-6.
- 15. Goettsch WG, S.D. B, N. B-P, Casparie M, Herings RM, P.C. H. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41(18):2868-72.
- 16. Breekveldt-Postma NS, Penning-van Beest FJ, Herings RMC. Utilisation pattern of fentanyl transdermal system in The Netherlands. Pharmacoepidemiol Drug Saf. 2005;14(2):129-34.
- 17. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388-94.
- 18. Beiderbeck-Noll AB, Sturkenboom MC, van der Linden PD, Herings RM, Hofman A, Coebergh JW, et al. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer. 2003;39(1):98-105.
- 19. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG. Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma. Am J Epidemiol. 2003;157(6):510-6.
- 20. Breekveldt-Postma NS, Zwart-van Rijkom JE, Egberts AC, Leufkens HG, Herings RM. Stijgende kosten van geneesmiddelen in ziekenhuizen in 1996-2000 en in de komende jaren. Ned Tijdschr Geneeskd. 2002;146(52):2547-51. Stijgende kosten van geneesmiddelen in ziekenhuizen in 1996-2000 en in de komende jaren.
- Diabetes
- 1. van den Haak P, Heintjes E, Plat AW, Jan Meerding W, Webb K, Sturkenboom MC, et al. Determination of non-treatment with statins of high risk patients in The Netherlands. Curr Med Res Opin. 2010;26(2):271-8.
- 2. Heintjes EM, Thomsen TL, Penning-van Beest FJ, Christensen TE, Herings RM. Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Adv Ther. 2010;27(4):211-22.
- 3. van der Linden MW, Plat AW, Erkens JA, Emneus M, Herings RM. Large Impact of Antidiabetic Drug Treatment and Hospitalizations on Economic Burden of Diabetes Mellitus in The Netherlands during 2000 to 2004. Value Health. 2009:909-14.
- 4. van der Linden MW, Penning-van Beest FJ, Nijsten T, Herings RM. Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands. Drug Saf. 2009;32(6):527-37.
- 5. Van der Linden MW, Gaugris S, Kuipers EJ, Van den Bemt BJ, van Herk-Sukel MP, Herings RM. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Curr Med Res Opin. 2009;25(1):195-204.
- 6. Plat A, Penning-van Beest F, Kessabi S, Groot M, Herings R. Change of initial oral antidiabetic therapy in type 2 diabetic patients. Pharm World Sci. 2009;31(6):622-6.
- 7. Schneeberger C, Stolk RP, Devries JH, Schneeberger PM, Herings RM, Geerlings SE. Differences in the pattern of antibiotic prescription profile and recurrence rate for possible urinary tract infections in women with and without diabetes. Diabetes Care. 2008;31(7):1380-5.
- 8. Penning-van Beest FJ, Wolffenbuttel BH, Herings RM. Haemoglobin A(1)(c) Goal Attainment in Relation to Dose in Patients with Diabetes Mellitus Taking Metformin : A Nested, Case-Control Study. Clin Drug Investig. 2008;28(8):487-93.
- 9. Knol MJ, Derijks HJ, Geerlings MI, Heerdink ER, Souverein PC, Gorter KJ, et al. Influence of antidepressants on glycaemic control in patients with diabetes mellitus. Pharmacoepidemiol Drug Saf. 2008;17(6):577-86.
- 10. Derijks HJ, Heerdink ER, De Koning FH, Janknegt R, Klungel OH, Egberts AC. The association between antidepressant use and hypoglycaemia in diabetic patients: a nested case-control study. Pharmacoepidemiol Drug Saf. 2008;17(4):336-44.
- 11. Knol MJ, Geerlings MI, Egberts AC, Gorter KJ, Grobbee DE, Heerdink ER. No increased incidence of diabetes in antidepressant users. Int Clin Psychopharmacol. 2007;22(6):382-6.
- 12. van de Garde EM, Souverein PC, van den Bosch JM, Deneer VH, Leufkens HG. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J. 2006;27(6):1217-22.
- 13. Storimans MJ, Klungel OH, Talsma H, de Blaey CJ. Regional Influences on the Dispensing of Glucose Test Strips in Dutch Community Pharmacies. Pharm World Sci. 2006;28(1):26-32.
- 14. Storimans MJ, Talsma H, Klungel OH, de Blaey CJ. Dispensing glucose test materials in Dutch community pharmacies. Pharm World Sci. 2004;26(1):52-5.
- 15. Spoelstra JA, Stolk RP, Klungel OH, Erkens JA, Rutten GE, Leufkens HG, et al. Initiation of glucose-lowering therapy in Type 2 diabetes mellitus patients in general practice. Diabet Med. 2004;21(8):896-900.
- 16. Spoelstra JA, Stolk RP, Cohen D, Klungel OH, Erkens JA, Leufkens HG, et al. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry. 2004;65(5):674-8.
- 17. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388-94.
- 18. Erkens JA, Klungel OH, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients. Pharmacoepidemiol Drug Saf. 2004;13(3):139-46.
- 19. Spoelstra JA, Stolk RP, Heerdink ER, Klungel OH, Erkens JA, Leufkens HG, et al. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidemiol Drug Saf. 2003;12(2):121-7.
- 20. Erkens J, Klungel O, Stolk R, Grobbee D, Leufkens H. Belaagd aan alle zijden: Multifactoriële behandeling van diabetes mellitus type 2. Pharm Weekblad. 2003;2003(138):1574-9.
- 21. Spoelstra JA, Stol RP, de Bruyne MC, Erkens JA, Herings RM, Leufkens HG, et al. Factors associated with switching from oral hypoglycaemic agents to insulin therapy. Neth J Med. 2002;60(6):243-8.
- 22. Souverein PC, Herings RM, Man in 't Veld AJ, de la Rosette JJ, Farmer RD, Leufkens HG. Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia. Eur Urol. 2002;42(3):254-61.
- 23. Erkens JA, Klungel OH, Herings RM, Stolk RP, Spoelstra JA, Grobbee DE, et al. Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients. Eur Heart J. 2002;23(20):1575-9.
- 24. Erkens JA, Herings RM, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Cardiovascular risk factors and diseases precede oral hypoglycaemic therapy in patients with type 2 diabetes mellitus. J Clin Epidemiol. 2002;55(4):345-9.
- 25. Erkens JA, Klungel OH, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. Diabetes Care. 2001;24(8):1428-32.
- 26. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 1995;345(8959):1195-8.
- 27. Herings RM, de Boer A, Stricker BH, Bakker A, Sturmans F. A rapid method to estimate the incidence rate and prevalence of insulin-dependent diabetes mellitus in children 0-19 years of age. Pharm-World-Sci. 1995;17(1):17-9.
- Osteoporosis
- 1. Milder IE, Klungel OH, Mantel-Teeuwisse AK, Verschuren WM, Bemelmans WJ. Relation between body mass index, physical inactivity and use of prescription drugs: the Doetinchem Cohort Study. Int J Obes (Lond). 2010;34(6):1060-9.
- 2. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(2 Suppl):S3-13.
- 3. Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T, et al. Risk of hip/femur fracture after stroke: a population-based case-control study. Stroke. 2009;40(10):3281-5.
- 4. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008;24(5):1337-44.
- 5. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19(4):511-7.
- 6. Meijer WM, Beest FJ, Olson M, Herings RM. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Curr Med Res Opin. 2008;24(11):3217-22.
- 7. Goettsch WG, de Jong RB, Kramarz P, Herings RM. Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study. Pharmacoepidemiol Drug Saf. 2007;16(2):166-72.
- 8. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236-42.
- 9. Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int. 2004;15(2):120-4.
- 10. Schoofs MW, van der Klift M, Hofman A, de Laet CE, Herings RM, Stijnen T, et al. Thiazide diuretics and the risk for hip fracture. Annals of internal medicine. 2003;139(6):476-82.
- 11. Burger H, Herings RM, Egberts AC, Neef C, Leufkens HG. Cyclical etidronate use is not associated with symptoms of peptic ulcer disease. Eur J Clin Pharmacol. 2000;56(4):319-22.
- Children
- 1. Hodgkins P, Sasane R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther. 2011;33(2):188-203.
- 2. Sasane R, Hodgkins P, Meijer W. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. Curr Med Res Opin. 2010;26(11):2565-74.
- 3. Meijer WM, Faber A, van den Ban E, Tobi H. Current issues around the pharmacotherapy of ADHD in children and adults. Pharm World Sci. 2009;31(5):509-16.
- 4. Breekveldt-Postma NS, Koerselman J, Erkens JA, van der Molen T, Lammers JW, Herings RM. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf. 2008;17(4):411-22.
- 5. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, et al. Early Evidence on the Effects of Regulators' Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents. Am J Psychiatry. 2007;164(9):1356-63.
- 6. Hugtenburg JG, Heerdink ER, Egberts AC. Increased psychotropic drug consumption by children in the Netherlands during 1995-2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol. 2004;60(5):377-9.
- 7. Herings RM, de Boer A, Stricker BH, Bakker A, Sturmans F. A rapid method to estimate the incidence rate and prevalence of insulin-dependent diabetes mellitus in children 0-19 years of age. Pharm-World-Sci. 1995;17(1):17-9.
- Respiratory
- 1. Velthove KJ, Leufkens HG, Schweizer RC, van Solinge WW, Souverein PC. Medication changes prior to hospitalization for obstructive lung disease: a case-crossover study. Ann Pharmacother. 2010;44(2):267-73.
- 2. de Vries F, Pouwels S, Bracke M, Lammers JW, Leufkens H, Klungel O, et al. Use of inhaled corticosteroids and the risk of non-fatal acute myocardial infarction. J Hypertens. 2008;26(1):124-9.
- 3. de Vries F, Pouwels S, Bracke M, Lammers JW, Klungel O, Leufkens H, et al. Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol. 2008;65(4):580-6.
- 4. de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, et al. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2007;16(6):612-9.
- 5. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101(7):1398-405.
- 6. van de Garde EM, Souverein PC, van den Bosch JM, Deneer VH, Leufkens HG. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J. 2006;27(6):1217-22.
- 7. Breekveldt-Postma NS, Penning-van Beest FJA, Lammers J-W, Herings RMC. Astmabehandeling in de praktijk moeilijk vol te houden. Modern Medicine. 2005(5):36-9.
- 8. Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RMC. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med. 2004;98(8):752-9.
- 9. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5):795-8.
- 10. Herings RMC. Meer astma en COPD; beter behandeld. Pharm Weekblad. 2002;137(1):17-9.
- 11. Westein MP, Herings RM, Leufkens HG. Determinants of pharmacists' interventions linked to prescription processing. Pharm World Sci. 2001;23(3):98-101.
- 12. Bouvy ML, Heerdink ER, De Bruin ML, Herings RM, Leufkens HG, Hoes AW. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med. 2000;160(16):2477-80.
- NSAIDs and Protonpump Inhibitors
- 1. Valkhoff VE, t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 2010;33(1):77-88.
- 2. van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2009;68(5):668-73.
- 3. van der Linden MW, Gaugris S, Kuipers EJ, van Herk-Sukel MP, van den Bemt BJ, Sen SS, et al. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiol Drug Saf. 2009;18(10):880-90.
- 4. Van der Linden MW, Gaugris S, Kuipers EJ, Van den Bemt BJ, van Herk-Sukel MP, Herings RM. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Curr Med Res Opin. 2009;25(1):195-204.
- 5. Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol. 2009;129(11):2620-7.
- 6. Sukel MP, van der Linden MW, Chen C, Erkens JA, Herings RM. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiol Drug Saf. 2008;17(1):9-19.
- 7. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008;24(5):1337-44.
- 8. Penning-van Beest FJA, Herings RMC. Generiek omeprazol als eerstekeuze-PPI: beleid versus praktijk. Modern Medicine. 2007;31(4):163-4.
- 9. Penning-van Beest FJ, Koerselman J, Herings RM. Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci. 2007;29(6):671-5.
- 10. Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, et al. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer. 2007;43(17):2580-9.
- 11. ten Berg MJ, Huisman A, Souverein PC, Schobben AF, Egberts AC, van Solinge WW, et al. Drug-induced thrombocytopenia: a population study. Drug Saf. 2006;29(8):713-21.
- 12. ten Berg MJ, Goettsch WG, van den Boom G, Smout AJ, Herings RM. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. Eur J Gastroenterol Hepatol. 2006;18(5):475-81.
- 13. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236-42.
- 14. Breekveldt-Postma NS, Herings RM. Persistence with antihypertensives related to formulation: the case of nifedipine. Ann Pharmacother. 2005;39(2):237-42.
- 15. Herings RM, Goettsch WG. Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother. 2004;38(5):760-3.
- 16. Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID- induced gastrointestinal events in The Netherlands. Pharmacoeconomics. 2001;19(6):655-65.
- 17. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158(10):1108-12.
- 18. van der Klauw MM, Stricker BH, Herings RM, Cost WS, Valkenburg HA, Wilson JH. A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol. 1993;35(4):400-8.
- 19. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health. 1992;46(2):136-40.
- Persistence and compliance
- 1. Penning-van Beest FJA, van Herk-Sukel MP, Gale R, Lammers JW, Herings R. Three-year dispensing patterns with long-acting inhaled drugs in COPD: A database analysis. Respir Med. 2011;105(2):259-65.
- 2. Kroger E, van Marum R, Souverein P, Egberts T. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study. Drugs Aging. 2010;27(8):663-75.
- 3. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(2 Suppl):S3-13.
- 4. van Wijk BL, Shrank WH, Klungel OH, Schneeweiss S, Brookhart MA, Avorn J. A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens. 2008;26(1):145-53.
- 5. Penning-van Beest FJA, van der Bij S, Erkens JA, Kessabi S, Groot M, Herings RM. Effect on non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment. Curr Med Res Opin. 2008;24(9):2523-9.
- 6. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Koerselman J, Klungel OH, Falvey H, et al. Effect of persistent use of antihypertensives on blood pressure goal attainment. Curr Med Res Opin. 2008;24(4):1025-31.
- 7. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008;24(1):121-7.
- 8. Breekveldt-Postma NS, Koerselman J, Erkens JA, van der Molen T, Lammers JW, Herings RM. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf. 2008;17(4):411-22.
- 9. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Effect of drug combinations on admission for recurrent myocardial infarction. Heart. 2007;93(10):1226-30.
- 10. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007;28(2):154-9.
- 11. Menckeberg TT, Belitser SV, Bouvy ML, Bracke M, Lammers JW, Raaijmakers JA, et al. Distinguishing patterns in the dynamics of long-term medication use by Markov analysis: beyond persistence. BMC Health Serv Res. 2007;7:106.
- 12. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101(7):1398-405.
- 13. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol. 2006;59(1):11-7.
- 14. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother. 2006;40(1):15-20.
- 15. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236-42.
- 16. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23(11):2101-7.
- 17. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis. Clin Ther. 2005;27(11):1806-14.
- 18. Erkens JA, Panneman MM, Klungel OH, Boom GV, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14(11):795-803.
- 19. Breekveldt-Postma NS, Herings RM. Persistence with antihypertensives related to formulation: the case of nifedipine. Ann Pharmacother. 2005;39(2):237-42.
- 20. Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int. 2004;15(2):120-4.
- 21. Mantel-Teeuwisse AK, Klungel OH, Egberts TC, Verschuren WM, Porsius AJ, de Boer A. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug Saf. 2004;27(1):63-70.
- 22. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart. 2004;90(9):1065-6.
- 23. Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RMC. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med. 2004;98(8):752-9.
- Myocardial Infarction
- 1. van Herk-Sukel MP, Shantakumar S, Kamphuisen PW, Penning-van Beest FJ, Herings RM. Myocardial infarction, ischaemic stroke and pulmonary embolism before and after breast cancer hospitalisation. A population-based study. Thromb Haemost. 2011;106(1).
- 2. Trifiro G, Patadia V, Schuemie MJ, Coloma PM, Gini R, Herings R, et al. EU-ADR Healthcare Database Network vs. Spontaneous Reporting System Database: Preliminary Comparison of Signal Detection. Stud Health Technol Inform. 2011;166:25-30.
- 3. Hodgkins P, Sasane R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther. 2011;33(2):188-203.
- 4. Valkhoff VE, t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 2010;33(1):77-88.
- 5. Peters BJ, Rodin AS, Klungel OH, Stricker BH, de Boer A, Maitland-van der Zee AH. Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenet Genomics. 2010;20(12):766-74.
- 6. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, et al. Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer. J Clin Oncol. 2010(28):2423-9.
- 7. de Peuter OR, Lip GY, Souverein PC, Klungel OH, de Boer A, Buller HR, et al. Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. Eur J Heart Fail. 2010:in press.
- 8. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol. 2009;130(4):962-7.
- 9. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Stricker BH, Kroon AA, de Leeuw PW, et al. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci. 2009;31(2):158-64.
- 10. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, et al. Reasons for non-response in observational pharmacogenetic research. Pharmacoepidemiol Drug Saf. 2009;18(8):665-71.
- 11. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, et al. Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. J Hypertens. 2009;27(1):61-8.
- 12. van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2009;68(5):668-73.
- 13. van der Linden MW, Gaugris S, Kuipers EJ, van Herk-Sukel MP, van den Bemt BJ, Sen SS, et al. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiol Drug Saf. 2009;18(10):880-90.
- 14. Van der Linden MW, Gaugris S, Kuipers EJ, Van den Bemt BJ, van Herk-Sukel MP, Herings RM. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Curr Med Res Opin. 2009;25(1):195-204.
- 15. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(2 Suppl):S3-13.
- 16. Heintjes EM, Penning-van Beest FJ, Johansson S, Stalenhoef AF, Herings RM. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Curr Med Res Opin. 2009;25(11):2621-9.
- 17. Peters BJ, Maitland-van der Zee AH, Stricker BH, van Wieren-de Wijer DB, de Boer A, Kroon AA, et al. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenet Genomics. 2008;18(7):631-6.
- 18. de Vries F, Pouwels S, Bracke M, Lammers JW, Leufkens H, Klungel O, et al. Use of inhaled corticosteroids and the risk of non-fatal acute myocardial infarction. J Hypertens. 2008;26(1):124-9.
- 19. de Vries F, Pouwels S, Bracke M, Lammers JW, Klungel O, Leufkens H, et al. Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol. 2008;65(4):580-6.
- 20. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008;24(1):121-7.
- 21. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Effect of drug combinations on admission for recurrent myocardial infarction. Heart. 2007;93(10):1226-30.
- 22. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007;28(2):154-9.
- 23. Menckeberg TT, Belitser SV, Bouvy ML, Bracke M, Lammers JW, Raaijmakers JA, et al. Distinguishing patterns in the dynamics of long-term medication use by Markov analysis: beyond persistence. BMC Health Serv Res. 2007;7:106.
- 24. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother. 2006;40(1):15-20.
- 25. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Improving pharmacotherapy after myocardial infarction by group academic detailing using feedback data on a patient level. Pharmacotherapy. 2006;
- 26(2):254-9. 26. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis. Clin Ther. 2005;27(11):1806-14.
- 27. Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int. 2004;15(2):120-4.
- 28. van der Elst ME, Cisneros-Gonzalez N, de Blaey CJ, Buurma H, de Boer A. Oral antithrombotic use among myocardial infarction patients. Ann Pharmacother. 2003;37(1):143-6.
- 29. Spoelstra JA, Stol RP, de Bruyne MC, Erkens JA, Herings RM, Leufkens HG, et al. Factors associated with switching from oral hypoglycaemic agents to insulin therapy. Neth J Med. 2002;60(6):243-8.
- 30. Breekveldt-Postma NS, Zwart-van Rijkom JE, Egberts AC, Leufkens HG, Herings RM. Stijgende kosten van geneesmiddelen in ziekenhuizen in 1996-2000 en in de komende jaren. Ned Tijdschr Geneeskd. 2002;146(52):2547-51. Stijgende kosten van geneesmiddelen in ziekenhuizen in 1996-2000 en in de komende jaren.
- 31. Herings RM, Leufkens HG, Vandenbroucke JP. Acute myocardial infarction and prior antibiotic use. JAMA : the journal of the American Medical Association. 2000;284(23):2998-9.
Other questions? Please send us an e-mail: pharmo@pharmo.nl